brand logo

Am Fam Physician. 2022;106(4):459-460

Author disclosure: No relevant financial relationships.

The Galleri test is a multicancer early detection blood test used to identify more than 50 cancer types in asymptomatic adults 50 years or older.1,2 It uses artificial intelligence analysis of cell-free DNA to recognize patterns associated with cancer and identify the likely tissue of origin. The Galleri test is not meant to replace current population-based cancer screening recommendations and is not approved by the U.S. Food and Drug Administration.3

TestIndicationPopulation, frequencyCost*
Galleri multi-cancer early detection testDetection of more than 50 cancer typesAsymptomatic adults with an elevated risk for cancer (such as those 50 years or older); performed annually$949


An industry-funded prospective, multicenter, observational study characterized genomic cancer signals in blood samples of patients with and without cancer.4 The study enrolled 15,254 patients (56% with known cancer) and divided them into three substudies: discovery, training, and clinical validation. The discovery and training phases created a targeted methylation analysis of circulating cell-free DNA and assessed its performance in detecting and localizing multiple cancer types. Of note, comparing the test in patients who have known disease with healthy control patients will overestimate accuracy.

In the clinical validation phase, 2,823 patients with a cancer diagnosis and 1,254 patients without were assessed for cancer status after one year.4 The study did not report what proportion of patients with cancer were diagnosed using screening tests vs. those who presented with cancer symptoms. Specificity of the Galleri test for cancer signal detection was 99.5%. Overall sensitivity for cancer signal detection was 51.5% and increased with stage (I: 16.8%; II: 40.4%; III: 77.0%; IV: 90.1%). Sensitivity in stages I to III was 67.6% for the 12 prespecified cancer types that account for approximately two-thirds of annual U.S. cancer deaths and was 40.7% for all cancer types. Sensitivities for the 12 cancer types are shown in Table 1.46 Cancer signals were detected in more than 50 cancer types. The Galleri test correctly predicted cancer tissue of origin in 88.7% of true-positive cases.4

Cancer typeSensitivity of Galleri test4 (95% CI)Traditional screening test for asymptomatic patients
Anus81.8% (61.5% to 92.7%)NA
Bladder34.8% (18.8% to 55.1%)NA
Colon/rectum82.0% (76.2% to 86.7%)Sensitivity = 75% (95% CI, 63% to 84%) to 93% (95% CI, 88% to 96%)5
Esophagus85.0% (76.7% to 90.7%)NA
Head and neck85.7% (77.8% to 91.1%)NA
Liver/bile duct93.5% (82.5% to 97.8%)NA
Lung74.8% (70.3% to 78.7%)Sensitivity = 59% to 100% (95% CI not reported)6
Lymphoma56.3% (48.9% to 63.5%)NA
Ovary83.1% (72.2% to 90.3%)Not recommended*
Pancreas83.7% (76.6% to 89.0%)Not recommended*
Plasma cell neoplasm72.3% (58.2% to 83.1%)NA
Stomach66.7% (48.8% to 80.8%)NA

In a 2021 prospective interim analysis, 4,033 patients received Galleri testing, and clinical evaluation for cancer was performed if results were positive. A cancer signal was detected in 62 patients (1.5%). Of these patients, 40 reached diagnostic resolution; 18 had true-positive results and 22 had false-positive results after imaging and other diagnostic procedures (positive predictive value = 45%). Accuracy of the top cancer signal origin prediction in true-positive cases was 82.4%. Most cancers detected were diagnosed at stages I to III.7

Observational studies are ongoing for breast and lung cancers.8,9 Patients in these studies have provided blood samples, and traditional screening methods will be used to evaluate the performance of the Galleri test. A study in the United Kingdom is currently enrolling 140,000 National Health Service patients between 50 and 77 years of age to further evaluate test performance.10


The Galleri test uses a blood draw and does not require a physician visit. This may be more convenient for patients living in rural or remote communities or who have other barriers to seeing a physician or accessing specialty or screening services. The Galleri test may help reduce racial and socioeconomic disparities in cancer screening adherence, but more research is needed.

Earlier diagnosis of cancer through Galleri testing has the potential to improve patient survival, although this has not been empirically demonstrated. Although most cancers are diagnosed in late stages, the Galleri test can screen for some cancers that do not have effective population-based screening options, which account for about 70% of cancer deaths in the United States.11


Because the Galleri test is not a diagnostic tool, a positive result must be confirmed in accordance with standard medical practice. Diagnostic decisions are the responsibility of the ordering physician. For some forms of cancer, there may be no effective treatment. When a cancer signal is detected, the likelihood that the individual has cancer remains elevated and may warrant further evaluation even after a negative diagnostic evaluation of the cancer signal origin(s). However, this process is not well defined and could lead to greater cost and harms.

Already a member/subscriber?  Log In


From $145
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available

Issue Access

  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

This series is coordinated by Natasha Pyzocha, DO, contributing editor.

A collection of Diagnostic Tests published in AFP is available at

Continue Reading

More in AFP

More in Pubmed

Copyright © 2022 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.